4.6 Review

Prevalence of celiac disease in patients with short stature: A systematic review and meta-analysis

Journal

JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY
Volume 36, Issue 1, Pages 44-54

Publisher

WILEY
DOI: 10.1111/jgh.15167

Keywords

Celiac disease; Enteropathy; Growth retardation; Idiopathic short stature; Prevalence

Ask authors/readers for more resources

The study found that the prevalence of celiac disease was 11.2% for patients with all-cause short stature and 9.7% for patients with idiopathic short stature, with biopsy-confirmed celiac disease rates of 7.4% and 11.6%, respectively. Evaluating for celiac disease may be beneficial for all patients with short stature.
Background and Aim Short stature is a common extraintestinal manifestation of celiac disease (CeD). We conducted a systematic review and meta-analysis to assess the global prevalence of CeD in patients presenting with short stature. Methods We searched Medline and EMBASE databases for the keywords celiac disease, coeliac disease, anti-gliadin, tissue transglutaminase antibody, anti-endomysial antibody, short stature and growth retardation. All the studies published from January 1991 to May 2020 were included. Patients without any prior evaluation for short stature were classified as all-cause short stature, while prior evaluated patients, where no cause was found for short stature, were classified as idiopathic short stature. The diagnosis of CeD was based on the European Society for Paediatric Gastroenterology, Hepatology and Nutrition guidelines. A random-effects model was used to pool the data. Results Seventeen studies screening 3759 patients (1582 with all-cause short stature and 2177 with idiopathic short stature) were included. The pooled seroprevalence of CeD based on positive anti-tissue transglutaminase antibody and anti-endomysial antibody was 11.2% (95% CI 4.0-21.2%;I-2 = 86%) and 9.7% (95% CI 2.7-20.2%;I-2 = 95%) for all-cause and idiopathic short stature, respectively. Similarly, pooled prevalence of biopsy-confirmed CeD was 7.4% (95% CI 4.7-10.6%;I-2 = 76%) and 11.6% (95% CI 4.1-22.2%;I-2 = 97%), for all-cause and idiopathic short stature, respectively. There was an overall severe risk of selection bias and significant heterogeneity in the pooled results. Conclusions Approximately one in 14 patients with all-cause short stature and one in nine patients with idiopathic short stature had biopsy-confirmed CeD. Therefore, evaluation for CeD may be prudent in all patients with short stature.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.6
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available